🔗 Share this article Patients Coming Off Anti-Obesity Medications Regain Weight at a Quadrupled Rate Than Those on Conventional Diets Obesity treatment involves long-term strategies. Fresh analysis suggests that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on lost weight far faster than those who end traditional lifestyle regimens. Published data in a major medical journal shows that while overweight individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation. "Individuals buying such medications should be cognizant of the danger of fast weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb. That rate of regain implies a return to pre-treatment mass in about a year and a half. Weighing Therapies The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods. Researchers point out that people who shed pounds through diet and exercise usually experience a more gradual weight regain—approximately 0.1 kg a month—after stopping. The Reason for the Rapid Rebound Experts propose the mechanism of the drugs is key to understanding the accelerated weight return. These medications copy a body's own chemical called GLP-1, which controls hunger. "Long-term administration of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk." An Ongoing Disease? The NHS advise the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes. Many experts argue that, due to the likelihood of relapse, the therapy is often long-term. This view is reinforced by drug manufacturers, who state that the findings "underscore the long-term character of obesity," akin to managing diseases like hypertension. User Testimonies People who have come off the jabs report a powerful resurgence of cravings. "It felt as if something that goes on and you're instantly extremely hungry," described an individual. This challenge is worsened if users have not established lasting dietary or behavioural modifications during treatment. Widespread Adoption Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial. Adoption is more common among women than men. The 40s and 50s demographic shows the highest usage rates. Many obtain the medications through private healthcare rather than public health services. Ultimately, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and long-term success relies on combined lifestyle changes.
Obesity treatment involves long-term strategies. Fresh analysis suggests that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on lost weight far faster than those who end traditional lifestyle regimens. Published data in a major medical journal shows that while overweight individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation. "Individuals buying such medications should be cognizant of the danger of fast weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb. That rate of regain implies a return to pre-treatment mass in about a year and a half. Weighing Therapies The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods. Researchers point out that people who shed pounds through diet and exercise usually experience a more gradual weight regain—approximately 0.1 kg a month—after stopping. The Reason for the Rapid Rebound Experts propose the mechanism of the drugs is key to understanding the accelerated weight return. These medications copy a body's own chemical called GLP-1, which controls hunger. "Long-term administration of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating a significant risk." An Ongoing Disease? The NHS advise the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes. Many experts argue that, due to the likelihood of relapse, the therapy is often long-term. This view is reinforced by drug manufacturers, who state that the findings "underscore the long-term character of obesity," akin to managing diseases like hypertension. User Testimonies People who have come off the jabs report a powerful resurgence of cravings. "It felt as if something that goes on and you're instantly extremely hungry," described an individual. This challenge is worsened if users have not established lasting dietary or behavioural modifications during treatment. Widespread Adoption Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial. Adoption is more common among women than men. The 40s and 50s demographic shows the highest usage rates. Many obtain the medications through private healthcare rather than public health services. Ultimately, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and long-term success relies on combined lifestyle changes.